title: A phase II study of cisplatinum and continuous infusion 5-fluorouracil for metastatic melanoma.
abstract: Advanced or metastatic melanoma responds poorly to chemotherapy, which has no impact on survival. Responses have been recorded using cisplatinum as a single agent. This study tested the established combination of cisplatinum 100 mg/m2 and 5-fluorouracil 1 g/m2/day continuously intravenously for 5 days repeated every 3 weeks in patients with disseminated melanoma. Twenty-nine patients, 13 having received no prior systemic chemotherapy, received 49 cycles of therapy (median 1, range 1-4). Only one previously untreated patient achieved a partial response with a failure-free survival of 6.5 months and an overall survival of 7.7 months from the commencement of therapy. The major toxicities were nausea and vomiting, (grade 3 in eight patients), stomatitis (grade 4 in two patients, grade 3 in two patients), and myelosuppression. The study showed that cisplatin and 5-fluorouracil have a low order of activity in patients with advanced or disseminated melanoma.
authors.affiliation: Peter McCallum Cancer Institute, Melbourne, Australia.
authors.forename: I N
authors.initials: IN
authors.lastname: Olver
authors.forename: J F
authors.initials: JF
authors.lastname: Bishop
authors.forename: M
authors.initials: M
authors.lastname: Green
authors.forename: A
authors.initials: A
authors.lastname: Zimet
authors.forename: C
authors.initials: C
authors.lastname: Laidlaw
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D016019:Survival Analysis
chemical_list: D002945:Cisplatin; D005472:Fluorouracil